Hines Jacobi B, Bowar Benjamin C, Colleton Margaret, Chelala Lydia, Wang Peng, Chadha Angad A, Segal Jeremy, Bestvina Christine M
Department of Medicine, Section of Hematology and Oncology, University of Chicago Medical Center, Chicago, Illinois.
Department of Radiology, University of Chicago Medical Center, Chicago, Illinois.
JTO Clin Res Rep. 2024 Aug 28;5(11):100724. doi: 10.1016/j.jtocrr.2024.100724. eCollection 2024 Nov.
fusions are present in 1% to 2% of NSCLCs. Although RET inhibitors like selpercatinib are effective, resistance inevitably develops. We present the case of a 28-year-old female with recurrent NSCLC and a fusion treated with selpercatinib. Testing at the time of progression revealed a new :BRAF fusion. She was then treated with a combination of selpercatinib and trametinib, which led to a likely partial response, despite the combination demonstrating side effects. This case report details the first known instance of NSCLC with a fusion developing resistance by means of a fusion, treated with combined RET and MEK inhibition.
融合在1%至2%的非小细胞肺癌（NSCLC）中存在。尽管像塞尔帕替尼这样的RET抑制剂有效，但耐药性不可避免地会出现。我们报告了一例28岁复发性NSCLC女性患者，其 融合接受了塞尔帕替尼治疗。疾病进展时的检测发现了一种新的 ：BRAF融合。然后她接受了塞尔帕替尼和曲美替尼联合治疗，尽管联合治疗显示出副作用，但仍产生了可能的部分缓解。本病例报告详细介绍了首例已知的具有 融合的NSCLC通过 融合产生耐药性，并接受RET和MEK联合抑制治疗的病例。
